Dexamethasone

Generic Name: Dexamethasone

Brand Names: Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₉FO_₅

CAS Number: 50-02-2

Unique Ingredient Identifier: 7S5I7G3JQL

Background: Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.

Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.

Indication: Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes

Associated Therapies: -

Clinical Trials

Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma

Phase 2

Completed

Conditions: Liposarcoma,Myxoid

Interventions: Drug: Trabectedin
Drug: Dexamethasone

First Posted Date: 2007-12-24

Last Posted Date: 2014-05-07

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 29

Registration Number: NCT00579501

Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients

Phase 3

Completed

Conditions: Lymphoma

Interventions: Drug: Fludarabine
Drug: Novantrone
Drug: Decadron
Drug: Interferon
Drug: Rituximab
Drug: Doxorubicin
Drug: Vincristine
Drug: Bleomycin
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Cisplatin
Drug: Ara-C
Drug: Methyl-Prednisolone
Drug: Procarbazine
Drug: Prednisone

First Posted Date: 2007-12-20

Last Posted Date: 2020-11-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 210

Registration Number: NCT00577993

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy

Phase 3

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Velcade
Drug: Thalidomide
Drug: Dexamethasone
Drug: Adriamycin
Drug: Cisplatin
Drug: Cyclophosphamide
Drug: Etoposide

First Posted Date: 2007-12-12

Last Posted Date: 2024-04-10

Lead Sponsor: University of Arkansas

Target Recruit Count: 177

Registration Number: NCT00572169

Locations: 🇺🇸
University of Arkansas for Medical Sciences/Myeloma Institute, Little Rock, Arkansas, United States

Nausea and Pain Prophylaxis During Thyroid Surgery

Not Applicable

Completed

Conditions: Thyroid Diseases
Parathyroid Diseases

Interventions: Drug: natriumchloride 0,9%
Drug: dexamethasone

First Posted Date: 2007-12-10

Last Posted Date: 2009-01-15

Lead Sponsor: Sykehuset Telemark

Target Recruit Count: 120

Registration Number: NCT00569920

Locations: 🇳🇴
Surgery Unit, Porsgrunn, Acute Care Clinic, Telemark Hospital, Porsgrunn, Telemark, Norway

Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis

Phase 2

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Drug: cyclophosphamide
Drug: dexamethasone
Drug: lenalidomide

First Posted Date: 2007-11-29

Last Posted Date: 2013-05-14

Lead Sponsor: Mayo Clinic

Target Recruit Count: 35

Registration Number: NCT00564889

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States

MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning

Phase 2

Completed

Conditions: Multiple Myeloma

First Posted Date: 2007-11-27

Last Posted Date: 2014-10-28

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 30

Registration Number: NCT00564200

Locations: 🇪🇸
H. de Jerez, Jerez de la Frontera, Spain
🇪🇸
Instituto Catalán de Oncología, Barcelona, Spain
🇪🇸
H. 12 de Octubre, Madrid, Spain

and more 7 locations

Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)

Phase 3

Terminated

Conditions: Lymphoma, Follicular

Interventions: Drug: inotuzumab ozogamicin
Drug: rituximab
Drug: cyclophosphamide
Drug: vincristine
Drug: prednisone/prednisolone
Drug: mitoxantrone
Drug: fludarabine
Drug: dexamethasone

First Posted Date: 2007-11-26

Last Posted Date: 2018-01-09

Lead Sponsor: Pfizer

Target Recruit Count: 29

Registration Number: NCT00562965

Locations: 🇺🇸
Wenatchee Valley Medical Center, Wenatchee, Washington, United States
🇺🇸
Park Nicollet Frauenshuh Cancer Center, Saint Louis Park, Minnesota, United States
🇺🇸
Facey Medical Group, Mission Hills, California, United States

and more 34 locations

Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Dasatinib
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2007-11-19

Last Posted Date: 2017-03-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 16

Registration Number: NCT00560352

Locations: 🇺🇸
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸
Orlando Health, Inc. M.D. Anderson Cancer Center Orlando, Orlando, Florida, United States
🇪🇸
Local Institution, Salamanca, Spain